The Ministry of Health of the Russian Federation has authorized a Russian originator drug for the treatment of unresectable or metastatic melanoma. The product was developed by BIOCAD, a biotechnology company; it is a fixed dose combination of two monoclonal antibodies, nurulimab and prolgolimab.
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches.
On June 16, GEROPHARM and the Government of Saint Petersburg at SPIEF-2023 signed a cooperation agreement to implement the investment project aimed at expanding the manufacture of medicinal products and increasing their export potential.
On June 8, at the Eurasia – Our Home exhibition, GEROPHARM and Karaganda Pharmaceutical Plant signed a long-term contract to localize the production of...
JSC “Pharmstandard” informs about the change to the membership of the Company's management and the appointment of Dmitry Ivanovich Zaytsev as Chief Executive Officer.
Potapov...